Cronos Group Inc.

CRON Healthcare Drug Manufacturers Specialty & Generic

Cronos Group Inc.’s revenue for fiscal 2025 (year ended December 2025) was $146.6 million, up 24.6% from fiscal 2024. In the quarter to June 2026, revenue grew 58.4%, EPS grew 190.0%, free cash flow grew 2,279.2% and total debt fell 4.71%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.

3.22 0.02 +0.63%
Market cap
$1.2B
P/E
16.1×
Fwd P/E
32.2×
Dividend yield
—
F-score
5/9
Altman Z
12.67
Beneish M
−2.05
Dividend safety
20/100
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

6 5 4 8
ROE
0.32% (3.72%) (3.07%) 3.33%
ROA
0.30% (3.55%) (2.95%) 3.18%
ROIC
(4.30%) (3.34%) (2.98%) (0.34%)
Return on Tangible Assets
0.35% (4.03%) (3.34%) 3.76%
Average Days of Receivables
104.78 142.42 119.52 116.26
Free Cash Flow per Share
(0.01) 0.00 0.07 0.13
Free Cash Flow
(5.74) (0.19) 26.19 49.44
Other line items

Show all line items

Columns are period end dates